Skip Navigation

European Heart Journal 1995 16(Supplement K):37-41; doi:10.1093/eurheartj/16.suppl_K.37
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bristow, M. R.
Right arrow Articles by Abraham, W. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bristow, M. R.
Right arrow Articles by Abraham, W. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Anti-adrenergic effects of angiotensin converting enzyme inhibitors

M. R. Bristow and W. T. Abraham

University of Colorado Health Sciences Center, Division of Cardiology Denver, Colorado, U.S.A.

Correspondence: Michael R Bristow, MD, PhD, University of Colorado Health Sciences Center, Division of Cardiology, 4200 E Ninth Avenue B139, Denver, Colorado 80262, U.S.A.

The renin-angiotensin and adrenergic nervous systems are cross-regulated compensatory mechanisms that are induced or activated in the failing heart. In ventricular myocardium, the activation of one of these systems leads to activation or induction of the other, resulting in co-amplification of cellular mechanisms that result in cardiac myocyte hypertrophy, hyperplasia of nonmyocytic tissue components increased contractility and heart rate; and increased ventricular volume. Although these changes serve to stabilize stroke volume and cardiac output following an insult to the myocardium, the chronic and continual activation of these systems produces ventricular dilatation and deleterious remodelling at a chamber level and progressive myocyte dysfunction at a cellular level Because these systems are cross-regulated inhibition of one of them attenuates the activity of the other. This appears to be especially true in the failing heart where angiotensin converting enzyme inhibitors can produce substantial anti-adrenergic effects in individuals with high levels of adrenergic activation. The anti-adrenergic properties of angiotensin converting enzyme inhibitors may be at least partially responsible for the salutary effects of these agents in the clinical setting of heart failure or ischaemic heart disease.

Key Words: Adrenergic nervous system • angiotensin converting enzyme inhibitors • heart failure • renin-angiotensin system


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
R. Bauer, V. Straub, A. Blain, K. Bushby, and G. A. MacGowan
Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy
Eur J Heart Fail, May 1, 2009; 11(5): 463 - 471.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.